Schedule 13G ownership disclosure
SYNAGEVA BIOPHARMA CORP
Security class unavailable · CUSIP: 87159A103
Event date: 2015-05-29
Legacy cover-page extraction is best effort and may not include every reporting person.
- Filing-level shares
- 1,763,818
- Percent of class
- 4.7000%
Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.
Source: SEC EDGAR filingFiling metadata
- Accession number
- 0001422848-15-000163
- Form type
- SC 13G
- Filer
- Capital Research Global Investors
- CIK
- CIK 1422848
- Filed
- Jun 10, 2015
- Reporting period
- May 29, 2015
- Description
- Schedule 13G beneficial ownership